RxDoctor Payments Data

Sharif Abdelfattah, DPM

Foot & Ankle Surgery · Sullivan, INNPI 1639605637

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. Zimmer Biomet accounts for 82.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $6,161 and has fallen 98.2% since, to $113 in 2025.

$10,593in general payments, 2019–2025

Across 37 payments — averaging $286.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$9K
  • Crossroads Orthopedics, LLC$924
  • Stryker$686
  • Orthofix Medical, Inc.$80
  • Kerecis Limited$52
  • Averitas Pharma Inc.$20
  • plus $94 from 6 others

What the payments were for

  • Consulting fees$6,12558%
  • Travel & lodging$2,86827%
  • Food & beverage$6766%
  • Education$9249%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,593 in reported general payments places this provider in the 70th percentile of 212 foot & ankle surgery providers in Indiana.

See all foot & ankle surgery providers in Indiana

Medicare billing

Part B allowed, 2024
$146,669
Medicare patients
361
Services billed
2,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.13$5,883
Gabapentin141$2,380
Duloxetine Hcl66$1,210
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen123$1,015
Pregabalin23$835
Gentamicin Sulfate13$564
Pentoxifylline14$310
Ketoconazole15$279
Potassium Chloride44$276
Levofloxacin63$243
Terbinafine Hcl21$241
Ammonium Lactate21$211
Cephalexin23$196
Doxycycline Hyclate12$180
Furosemide77$174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$15$5,88313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 212 foot & ankle surgery providers in Indiana.

Other foot & ankle surgery in Sullivan

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →